Latest Breaking News On - Trastuzumab deruxtecan - Page 1 : comparemela.com

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO Annual Meeting

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJeremy pantinSusanna ulahannanGerald falchookAbdul naqashTim larsonDavid spigelManish patelJoyce oshaughnessyMeredith mckeanTrastuzumab emtansineJessica thomes pepinAntonella cammarotaIshwaria subbiahDurvalumab olaparib

T-DXd Maintains Survival Advantage Over Physician s Choice of Therapy in HER2+ Metastatic Breast Cancer

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Soult ukpyolsiSouth koreaDaiichi sankyoBae kimDaehwa pharmaAsan medical centerEnsol bioscience incUniversity of ulsanBreast cancer annual congressCancer annualSung bae kimTrastuzumab deruxtecanHer2 positive breast cancer

Agnostic Approval of Trastuzumab Deruxtecan Ushers in New Option for Advanced HER2+ Solid Tumors

Ronan J. Kelly, MD, MBA, discusses the significance of the FDA approval of trastuzumab deruxtecan for pretreated, advanced HER2-positive solid tumors.

Baylor universityUnited statesWw caruth jrRonanj kellyTrastuzumab deruxtecanBaylor scott white healthImmunology at baylor university medical centerCollege of american pathologistsBaylor scottWhite healthNorth texasWhite charlesCancer centerBaylor university medical centerEndowed chairAmerican pathologists

Trastuzumab Deruxtecan Shows Improvement in PFS in Patients With HR+, HER2-Low Metastatic Breast Cancer

The investigators note that additional research is needed to confirm positive overall survival trends in this patient population.

Ken takeshitaSebastian kaulitzkiDaiichi sankyoSusan galbraithTrastuzumab deruxtecanHormone receptor positiveMetastatic breast cancerPreview dataRegulatory insightsNew metastatic breast cancer

DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.

Edwards kimTrastuzumab deruxtecanEvolving treatment landscapeFirst line trastuzumab deruxtecanNon small cell lung cancerHer2 nsclcHer2 mutated nsclcHer2 non small cell lung cancerAntibody drug conjugatesT dxdDestiny lung04